These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37665427)

  • 1. First Clostridioides difficile Recurrence Is Highest Following Concomitant Antimicrobial Administration During and Within 30 Days of Treatment.
    Chaar A; Damianos J; Rizwan R; Al-Nahhas H; Mansoor MS; Sharma P; Malik U; Feuerstadt P
    Dig Dis Sci; 2023 Nov; 68(11):4221-4229. PubMed ID: 37665427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Center, Retrospective Cohort Study Evaluating the Use of Probiotics for the Prevention of Hospital-Onset
    Shah PJ; Halawi H; Kay J; Akogun A; Wise S; Aly S; Daoura N; Putney D
    Hosp Pharm; 2023 Feb; 58(1):57-61. PubMed ID: 36644740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 7. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating
    Keats KR; Stitt TM; Chastain DB; Jivan BP; Matznick E; Waller JL; Clemmons AB
    J Oncol Pharm Pract; 2022 Apr; 28(3):542-550. PubMed ID: 33663290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
    Allegretti JR; Kao D; Phelps E; Roach B; Smith J; Ganapini VC; Kassam Z; Xu H; Fischer M
    Dig Dis Sci; 2019 Jun; 64(6):1668-1671. PubMed ID: 30632052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-
    Reveles KR; Gonzales-Luna AJ; Golan Y; Alonso CD; Guthmueller B; Tan X; Bidell MR; Pokhilko V; Crawford CV; Skinner AM
    Open Forum Infect Dis; 2024 Jul; 11(7):ofae341. PubMed ID: 39006315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B; Valentová H; Fojtík P; Urban O
    Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Experience of Bezlotoxumab for Prevention of
    Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
    Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
    J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
    Finn E; Andersson FL; Madin-Warburton M
    BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Microbiota Transplant in Severe and Non-Severe
    Popa D; Neamtu B; Mihalache M; Boicean A; Banciu A; Banciu DD; Moga DFC; Birlutiu V
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection.
    Cheng YW; Phelps E; Nemes S; Rogers N; Sagi S; Bohm M; El-Halabi M; Allegretti JR; Kassam Z; Xu H; Fischer M
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2234-2243.e1. PubMed ID: 31923639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.